Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tymbion
- Development stage
- Phase 4
- Lead developer
- InfluENT Medical
- Modality
- Small Molecules
- Administration
- Otic
01
Overview
Tymbion is a fixed-dose otic solution containing lidocaine hydrochloride and epinephrine for iontophoretic induction of local anesthesia in the tympanic membrane before tympanostomy tube placement. It is administered only with the Tula Iontophoresis System; lidocaine produces local anesthetic blockade of voltage-gated sodium channels, while epinephrine provides adrenergic vasoconstrictor activity. The product was developed with the Tula tympanostomy platform by Tusker Medical and is marketed within Smith+Nephew's Tula system. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190016C.pdf))
- Brand names
- Tymbion
02
Targets
ADRA1A (α1A)ADRB1 (β1)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Tymbion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tymbion.